Fortitude Advisory Group’s DexCom DXCM Stock Holding History

Fortitude Advisory Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-884	Closed	-$114K	–	494
2022 Q1	$114K	Buy	884 +48	+6%	+$5.25K	0.06%	320
2021 Q4	$112K	Buy	+836	New	+$120K	0.06%	327

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fortitude Advisory Group's DXCM Position: Q2 2022 in Review

Fortitude Advisory Group sold out of DexCom (DXCM) in Q2 2022, closing a stake of 884 shares — an estimated $114K sold.

Fortitude Advisory Group first reported a position in DXCM in Q4 2021 and held it in 2 quarters. The position peaked at $114K in Q1 2022. 797 funds tracked by Wall St. Rank hold DXCM as of Q2 2022.

Fortitude Advisory Group reported no remaining DexCom position as of Q2 2022 after selling out during the quarter.
Fortitude Advisory Group sold 884 DexCom shares in Q2 2022, an estimated $114K.
Fortitude Advisory Group first reported a position in DexCom in Q4 2021 and held it in 2 quarters.
Fortitude Advisory Group's DexCom position peaked at $114K in Q1 2022.
797 funds tracked by Wall St. Rank held DexCom as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.